Literature DB >> 22895795

[Psychopharmacological treatment in patients with somatoform disorders and functional body syndromes].

H P Kapfhammer1.   

Abstract

Somatoform disorders and functional body syndromes define a major, diagnostically heterogeneous group of patients with medically unexplained physical symptoms. Psychopharmacological approaches can be derived from the conceptualization of somatoform symptoms and syndromes within a biopsychosocial model. The survey presented focuses on randomized, double-blind and placebo-controlled studies. Antidepressants show a statistically and clinically relevant impact on many somatoform symptoms. In special reference to pain symptoms serotonergic and noradrenergic antidepressants seem to mediate a more favorable effect than selective serotonin reuptake inhibitors. For some functional body syndromes, e.g. irritable bowel syndrome and fibromyalgia, a major analgesic effect of antidepressants can be underlined as well. The empirical data for fibromyalgia, however, seem to be more convincing than for irritable bowel syndrome. Pregabalin holds an empirically well established position in the treatment of fibromyalgia. As yet there is no convincing psychopharmacological strategy for chronic fatigue syndrome. Probably due to the inherent relationships to anxiety, obsessive-compulsive and depressive disorders, both hypochondria and body dysmorphic disorder can be positively treated by serotonergic antidepressants as well.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895795     DOI: 10.1007/s00115-011-3446-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  110 in total

1.  Efficacy and safety of fluvoxamine in body dysmorphic disorder.

Authors:  K A Phillips; M M Dwight; S L McElroy
Journal:  J Clin Psychiatry       Date:  1998-04       Impact factor: 4.384

2.  A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.

Authors:  Katharine A Phillips; Ralph S Albertini; Steven A Rasmussen
Journal:  Arch Gen Psychiatry       Date:  2002-04

3.  Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.

Authors:  Lesley M Arnold; R Michael Gendreau; Robert H Palmer; Judy F Gendreau; Yong Wang
Journal:  Arthritis Rheum       Date:  2010-09

4.  An open trial of fluvoxamine for hypochondriasis.

Authors:  Brian A Fallon; Altamash I Qureshi; Franklin R Schneier; Arturo Sanchez-Lacay; Donna Vermes; Robert Feinstein; Joseph Connelly; Michael R Liebowitz
Journal:  Psychosomatics       Date:  2003 Jul-Aug       Impact factor: 2.386

5.  Venlafaxine treatment of fibromyalgia.

Authors:  Kemal Sayar; Gokhan Aksu; Ismail Ak; Mehmet Tosun
Journal:  Ann Pharmacother       Date:  2003-11       Impact factor: 3.154

6.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.

Authors:  Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

7.  The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Authors:  Philip J Mease; Daniel J Clauw; R Michael Gendreau; Srinivas G Rao; Jay Kranzler; Wei Chen; Robert H Palmer
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

8.  Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial.

Authors:  Gary Tabas; Mary Beaves; Jiping Wang; Paul Friday; Houssam Mardini; George Arnold
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

9.  A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder.

Authors:  Douglas Turkington; John B F Grant; Ian Nicol Ferrier; N Sanjay K Rao; Keith R Linsley; Allan H Young
Journal:  J Clin Psychiatry       Date:  2002-09       Impact factor: 4.384

10.  Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.

Authors:  Jon I Russell; Philip J Mease; Timothy R Smith; Daniel K Kajdasz; Madelaine M Wohlreich; Michael J Detke; Daniel J Walker; Amy S Chappell; Lesley M Arnold
Journal:  Pain       Date:  2008-04-18       Impact factor: 6.961

View more
  3 in total

1.  Pregabalin abuse and dependence in Germany: results from a database query.

Authors:  Maximilian Gahr; Roland W Freudenmann; Christoph Hiemke; Makus A Kölle; Carlos Schönfeldt-Lecuona
Journal:  Eur J Clin Pharmacol       Date:  2013-01-05       Impact factor: 2.953

2.  Non-specific, functional, and somatoform bodily complaints.

Authors:  Rainer Schaefert; Constanze Hausteiner-Wiehle; Winfried Häuser; Joram Ronel; Markus Herrmann; Peter Henningsen
Journal:  Dtsch Arztebl Int       Date:  2012-11-23       Impact factor: 5.594

3.  [Conversion disorders].

Authors:  C Fricke-Neef; C Spitzer
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.